V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

BioMarin Pharmaceutical Executive Compensation (FY25)

BMRN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Alexander Hardy
Latest say-on-pay support
=
April 7, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on BioMarin Pharmaceutical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 4, 2026
14 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
BioMarin Pharmaceutical brief$1,500Get the executive brief
Velarion Member, one year
504 figures on this page: 494 cited to the filing that reported them, 10 calculated from figures it prints. See the citations

More on BioMarin Pharmaceutical

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Alexander Hardy: $14,853,605 → $21,927,563 (47.6% higher)
Say-on-pay support: 93.8% → 87.0% (6.8 points lower)
CEO pay ratio: 95:1 → 109:1 (14.7% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is BioMarin Pharmaceutical's chief executive and what were they paid?
Total compensation for Alexander Hardy, President and Chief Executive Officer, came to $21,927,563 in fiscal 2025. Hardy's total moved 47.6% higher from the $14,853,605 reported for fiscal 2024.
What was BioMarin Pharmaceutical's say-on-pay result?
Shareholders supported the say-on-pay proposal with 87.0% of votes cast for or against in favor at the meeting held April 7, 2026 for fiscal 2025.
Which companies are in BioMarin Pharmaceutical's peer group?
Companies named in the disclosed peer group include Alnylam Pharmaceuticals, Inc., BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.), Biogen Inc., Exelixis, Inc. and Gilead Sciences, Inc., among others.
What is BioMarin Pharmaceutical's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 109:1, against median employee compensation of $201,036.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Jacques Bienaimé
CEO
◇—◇◇◇—◇◇
Henry Fuchs
President, Worldwide R&D
◇—◇◇◇—◇◇
Jeff Ajer
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
◇—◇◇◇—◇◇
Brian Mueller
Executive Vice President, Finance and CFO
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jean-Jacques Bienaimé
Former CEO and Former Chairman of the Board
Departed during or after this year
◇—◇◇◇—◇◇
Alexander Hardy
President and Chief Executive Officer
◇◇◇◇——◇◇
Henry Fuchs
President, Worldwide R&D
◇—◇◇◇—◇◇
C. Greg Guyer
Executive Vice President, Chief Technical Officer
◇—◇◇◇—◇◇
Jeff Ajer
Executive Vice President, Chief Commercial Officer
◇—◇◇◇—◇◇
Brian Mueller
Executive Vice President, Finance and CFO
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alexander Hardy
President and Chief Executive Officer
◇—◇◇◇—◇◇
Hank Fuchs
President, Worldwide Research and Development
◇—◇◇◇—◇◇
Gregory Friberg
Executive Vice President and Chief Research & Development Officer
◇◇◇◇◇—◇◇
Cristin Hubbard
Executive Vice President, Chief Commercial Officer
◇◇◇◇◇—◇◇
Brian Mueller
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
G. Eric Davis
Executive Vice President, Chief Legal Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alexander Hardy
President and Chief Executive Officer
◇—◇◇◇—◇◇
Gregory Friberg
Executive Vice President and Chief Research & Development Officer
◇—◇◇◇—◇◇
Brian Mueller
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Cristin Hubbard
Executive Vice President and Chief Commercial Officer
◇—◇◇◇—◇◇
C. Greg Guyer
Executive Vice President and Chief Technical Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alexander HardyPSU◇◇◇—◇—◇
Alexander HardyPSU◇◇◇—◇—◇
Alexander HardyPSU◇◇◇—◇—◇
Alexander HardyRSU◇——◇——◇
Alexander HardyPSU◇◇◇—◇—◇
Alexander HardyPSU◇◇◇◇◇—◇
Alexander HardyOPTION◇——◇—◇◇
Brian R. MuellerPSU◇◇◇◇◇—◇
Brian R. MuellerPSU◇◇◇—◇—◇
Brian R. MuellerPSU◇◇◇—◇—◇
Brian R. MuellerPSU◇◇◇—◇—◇
Brian R. MuellerRSU◇——◇——◇
Brian R. MuellerOPTION◇——◇—◇◇
C. Greg GuyerPSU◇◇◇—◇—◇
C. Greg GuyerPSU◇◇◇—◇—◇
C. Greg GuyerRSU◇——◇——◇
C. Greg GuyerPSU◇◇◇—◇—◇
C. Greg GuyerOptions/SARs◇——◇—◇◇
C. Greg GuyerPSU◇◇◇◇◇—◇
Cristin HubbardPSU◇◇◇◇◇—◇
Cristin HubbardPSU◇◇◇—◇—◇
Cristin HubbardRSU◇——◇——◇
Cristin HubbardPSU◇◇◇—◇—◇
Cristin HubbardPSU◇◇◇—◇—◇
Cristin HubbardOPTION◇——◇—◇◇
Greg GuyerPSU◇◇◇—◇—◇
Greg GuyerOPTION◇——◇—◇◇
Greg GuyerRSU◇——◇——◇
Greg GuyerPSU◇◇◇—◇—◇
Greg GuyerPSU◇◇◇—◇—◇
Gregory R. FribergPSU◇◇◇◇◇—◇
Gregory R. FribergPSU◇◇◇—◇—◇
Gregory R. FribergPSU◇◇◇—◇—◇
Gregory R. FribergPSU◇◇◇—◇—◇
Gregory R. FribergRSU◇——◇——◇
Gregory R. FribergOPTION◇——◇—◇◇
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
C. GuyerRSU◇◇——
Option◇—◇3/16/2035
RSU◇◇——
Option◇—◇3/14/2034
Option◇—◇3/14/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Cristin HubbardRSU◇◇——
Option◇—◇5/19/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/16/2035
Gregory FribergRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇9/29/2034
Option◇—◇3/16/2035
RSU◇◇——
Brian MuellerOption◇—◇3/14/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/14/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/14/2034
Option◇—◇3/16/2035
RSU◇◇——
RSU◇◇——
Alexander HardyRSU◇◇——
RSU◇◇——
Option◇—◇11/30/2033
Option◇—◇3/14/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇3/16/2035
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Richard A. Meier
Board chair
◇◇————◇
Robert J. Hombach
◇◇————◇
Willard Dere, M.D
◇◇————◇
Elizabeth McKee Anderson
◇◇————◇
Maykin Ho, Ph.D
◇◇————◇
Mark J. Enyedy
◇◇————◇
Athena Countouriotis, M.D
◇◇————◇
Timothy P. Walbert
◇◇————◇
Barbara W. Bodem
◇◇————◇
Ian T. Clark
◇◇————◇
David E.I. Pyott, M.D. (Hon.)
◇—————◇
Elaine J. Heron, Ph.D
◇—————◇
Alexander Hardy served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: Lesser of 10,000 shares/unvested RSUs or value equal to 5x cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alnylam Pharmaceuticals, Inc. ALNY
  • BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.) ONC
  • Biogen Inc. BIIB
  • Exelixis, Inc. EXEL
  • Gilead Sciences, Inc. GILD
  • Incyte Corporation INCY
  • Ionis Pharmaceuticals Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Neurocrine Biosciences, Inc. NBIX
  • Regeneron Pharmaceuticals, Inc. REGN
  • Sarepta Therapeutics, Inc. SRPT
  • Ultragenyx Pharmaceuticals Inc. RARE
  • United Therapeutics Corporation UTHR
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 7, 2026=◇◇◇
2024March 24, 2025=◇◇◇
2023May 21, 2024=◇◇◇
2022May 23, 2023=◇◇◇
2021May 24, 2022=◇◇◇
2020May 25, 2021=◇◇◇
2019May 27, 2020=◇◇◇
2018June 4, 2019=◇◇◇
2017June 5, 2018=◇◇◇
2016June 6, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Alexander Hardy (President and Chief Executive Officer), FY2025 total compensation $21,927,563 (base salary $1,130,769) [exec_comp, SEC accession 0001628280-26-026290, filed 2026-04-21]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when BioMarin Pharmaceutical files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact BioMarin Pharmaceutical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where BioMarin Pharmaceutical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether BioMarin Pharmaceutical's disclosed peer group is defensible, who names BioMarin Pharmaceutical back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
504 figures on this page: 494 cited to the filing that reported them, 10 calculated from figures it prints.
494 cited to the filing
10 calculated from the filing

Documents cited

  1. 0001628280-26-040812
    Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy
  2. 0001628280-26-026290
    2025 Non-Employee Director Compensation · Director Compensation · Grants of Plan-Based Awards · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
  3. 0001193125-25-125040
    Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy
  4. 0001048477-25-000045
    Executive Compensation Tables · Summary Compensation Table
  5. 0001193125-24-147013
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001048477-24-000058
    Executive Compensation Tables · Summary Compensation Table
  7. 0001193125-23-156584
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001308179-23-000635
    Executive Compensation Tables
  9. 0001193125-22-163800
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-21-177943
  11. 0001193125-20-157266
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-19-168283
  13. 0001193125-18-188224
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-201414
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “BioMarin Pharmaceutical executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BMRN (accessed 2026).
Short form: data: Velarion

The paid brief for BioMarin Pharmaceutical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
14 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about BioMarin Pharmaceutical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers BioMarin Pharmaceutical discloses

The companies named in BMRN's own disclosed peer group.

Alnylam Pharmaceuticals, Inc.BeOne Medicines Ltd. (f/k/a BeiGene, Ltd.)Biogen Inc.Exelixis, Inc.Gilead Sciences, Inc.Incyte CorporationIonis Pharmaceuticals Inc.Jazz Pharmaceuticals plcNeurocrine Biosciences, Inc.Regeneron Pharmaceuticals, Inc.Sarepta Therapeutics, Inc.Ultragenyx Pharmaceuticals Inc.United Therapeutics CorporationVertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy